-
1
-
-
0037169357
-
Cancer as a complex genetic trait: Tumor susceptibility in humans and mouse models
-
A. Balmain Cancer as a complex genetic trait: Tumor susceptibility in humans and mouse models Cell 108 2002 145-152
-
(2002)
Cell
, vol.108
, pp. 145-152
-
-
Balmain, A.1
-
2
-
-
0042881036
-
Cancer susceptibility in the mouse: Genetics, biology and implications for human cancer
-
P. Demant Cancer susceptibility in the mouse: Genetics, biology and implications for human cancer Nat. Rev. Genet. 4 2003 721-734
-
(2003)
Nat. Rev. Genet.
, vol.4
, pp. 721-734
-
-
Demant, P.1
-
3
-
-
0037732512
-
10 years of mouse cancer modifier loci: Human relevance
-
T.A. Dragani 10 years of mouse cancer modifier loci: Human relevance Cancer Res. 63 2003 3011-3018
-
(2003)
Cancer Res.
, vol.63
, pp. 3011-3018
-
-
Dragani, T.A.1
-
4
-
-
0034460530
-
Genomics and proteomics: The new millennium of drug discovery and development
-
M.J. Cunningham Genomics and proteomics: The new millennium of drug discovery and development J. Pharmacol. Toxicol. Methods 44 2000 291-300
-
(2000)
J. Pharmacol. Toxicol. Methods
, vol.44
, pp. 291-300
-
-
Cunningham, M.J.1
-
5
-
-
0035892305
-
Gene expression microarray analysis in cancer biology, pharmacology, and drug development: Progress and potential
-
P.A. Clarke R. te Poele R. Wooster P. Workman Gene expression microarray analysis in cancer biology, pharmacology, and drug development: Progress and potential Biochem. Pharmacol. 62 2001 1311-1336
-
(2001)
Biochem. Pharmacol.
, vol.62
, pp. 1311-1336
-
-
Clarke, P.A.1
te Poele, R.2
Wooster, R.3
Workman, P.4
-
6
-
-
0036549767
-
Discordant protein and mRNA expression in lung adenocarcinomas
-
G. Chen et al. Discordant protein and mRNA expression in lung adenocarcinomas Mol. Cell. Proteom. 1 2002 304-313
-
(2002)
Mol. Cell. Proteom.
, vol.1
, pp. 304-313
-
-
Chen, G.1
-
7
-
-
0030895921
-
A comparison of selected mRNA and protein abundances in human liver
-
L. Anderson J. Seilhamer A comparison of selected mRNA and protein abundances in human liver Electrophoresis 18 1997 533-537
-
(1997)
Electrophoresis
, vol.18
, pp. 533-537
-
-
Anderson, L.1
Seilhamer, J.2
-
8
-
-
0032979179
-
Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era
-
S.P. Gygi D.K. Han A.C. Gingras N. Sonenberg R. Aebersold Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era Electrophoresis 20 1999 310-319
-
(1999)
Electrophoresis
, vol.20
, pp. 310-319
-
-
Gygi, S.P.1
Han, D.K.2
Gingras, A.C.3
Sonenberg, N.4
Aebersold, R.5
-
9
-
-
0037309124
-
Novel approaches to map protein interactions
-
D. Figeys Novel approaches to map protein interactions Curr. Opin. Biotechnol. 14 2003 119-125
-
(2003)
Curr. Opin. Biotechnol.
, vol.14
, pp. 119-125
-
-
Figeys, D.1
-
11
-
-
0037434980
-
From genomics to proteomics
-
M. Tyers M. Mann From genomics to proteomics Nature 422 2003 193-197
-
(2003)
Nature
, vol.422
, pp. 193-197
-
-
Tyers, M.1
Mann, M.2
-
13
-
-
0037441560
-
Fulfilling the promise: Drug discovery in the post-genomic era
-
S.K. Chanda J.S. Caldwell Fulfilling the promise: Drug discovery in the post-genomic era Drug Discovery Today 8 2003 168-174
-
(2003)
Drug Discovery Today
, vol.8
, pp. 168-174
-
-
Chanda, S.K.1
Caldwell, J.S.2
-
15
-
-
1342287074
-
Novel angiogenic signaling pathways and vascular targets
-
R. Bicknell A.L. Harris Novel angiogenic signaling pathways and vascular targets Annu. Rev. Pharmacol. Toxicol. 44 2004 219-238
-
(2004)
Annu. Rev. Pharmacol. Toxicol.
, vol.44
, pp. 219-238
-
-
Bicknell, R.1
Harris, A.L.2
-
16
-
-
0042386124
-
Caveolae: Mining little caves for new cancer targets
-
L.A. Carver J.E. Schnitzer Caveolae: Mining little caves for new cancer targets Nat. Rev. Cancer 3 2003 571-581
-
(2003)
Nat. Rev. Cancer
, vol.3
, pp. 571-581
-
-
Carver, L.A.1
Schnitzer, J.E.2
-
17
-
-
2442620564
-
Tumor endothelial markers: New targets for cancer therapy
-
A. Nanda B. St Croix Tumor endothelial markers: New targets for cancer therapy Curr. Opin. Oncol. 16 2004 44-49
-
(2004)
Curr. Opin. Oncol.
, vol.16
, pp. 44-49
-
-
Nanda, A.1
St Croix, B.2
-
18
-
-
2642571660
-
Vascular-targeting therapies for treatment of malignant disease
-
D.W. Siemann D.J. Chaplin M.R. Horsman Vascular-targeting therapies for treatment of malignant disease Cancer 100 2004 2491-2499
-
(2004)
Cancer
, vol.100
, pp. 2491-2499
-
-
Siemann, D.W.1
Chaplin, D.J.2
Horsman, M.R.3
-
19
-
-
1642555578
-
Cancer metastasis therapeutic targets and drug discovery: Emerging small-molecule protein kinase inhibitors
-
T.K. Sawyer Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors Expert Opin. Invest. Drugs 13 2004 1-19
-
(2004)
Expert Opin. Invest. Drugs
, vol.13
, pp. 1-19
-
-
Sawyer, T.K.1
-
21
-
-
0037192458
-
Matrix metalloproteinase inhibitors and cancer: Trials and tribulations
-
L.M. Coussens B. Fingleton L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 295 2002 2387-2392
-
(2002)
Science
, vol.295
, pp. 2387-2392
-
-
Coussens, L.M.1
Fingleton, B.2
Matrisian, L.M.3
-
22
-
-
0037312899
-
The not-so innocent bystander: The microenvironment as a therapeutic target in cancer
-
A.C. Erickson M.H. Barcellos-Hoff The not-so innocent bystander: The microenvironment as a therapeutic target in cancer Expert Opin. Ther. Targets 7 2003 71-88
-
(2003)
Expert Opin. Ther. Targets
, vol.7
, pp. 71-88
-
-
Erickson, A.C.1
Barcellos-Hoff, M.H.2
-
24
-
-
0038265104
-
The extracellular matrix: A new turn-of-the-screw for anti-angiogenic strategies
-
L. Sanz L. Alvarez-Vallina The extracellular matrix: A new turn-of-the-screw for anti-angiogenic strategies Trends Mol. Med. 9 2003 256-262
-
(2003)
Trends Mol. Med.
, vol.9
, pp. 256-262
-
-
Sanz, L.1
Alvarez-Vallina, L.2
-
25
-
-
1642471690
-
Pharmacological modulation of local feedback mechanisms as a therapeutic approach in breast cancer treatment
-
C.F. Singer G. Hudelist A. Galid E. Kubista Pharmacological modulation of local feedback mechanisms as a therapeutic approach in breast cancer treatment Drugs Today (Barcelona) 39 2003 917-926
-
(2003)
Drugs Today (Barcelona)
, vol.39
, pp. 917-926
-
-
Singer, C.F.1
Hudelist, G.2
Galid, A.3
Kubista, E.4
-
26
-
-
0036992758
-
Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting
-
S.Y. Sung L.W. Chung Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting Differentiation 70 2002 506-521
-
(2002)
Differentiation
, vol.70
, pp. 506-521
-
-
Sung, S.Y.1
Chung, L.W.2
-
27
-
-
0037052641
-
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
-
P. Vihinen V.M. Kahari Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets Int. J. Cancer 99 2002 157-166
-
(2002)
Int. J. Cancer
, vol.99
, pp. 157-166
-
-
Vihinen, P.1
Kahari, V.M.2
-
28
-
-
0032724911
-
Novel mechanisms for antisense-mediated regulation of gene expression
-
B.F. Baker B.P. Monia Novel mechanisms for antisense-mediated regulation of gene expression Biochim. Biophys. Acta 1489 1999 3-18
-
(1999)
Biochim. Biophys. Acta
, vol.1489
, pp. 3-18
-
-
Baker, B.F.1
Monia, B.P.2
-
29
-
-
0032700656
-
Molecular mechanisms of action of antisense drugs
-
S.T. Crooke Molecular mechanisms of action of antisense drugs Biochim. Biophys. Acta 1489 1999 31-44
-
(1999)
Biochim. Biophys. Acta
, vol.1489
, pp. 31-44
-
-
Crooke, S.T.1
-
30
-
-
0034176085
-
Elucidating cell signaling mechanisms using antisense technology
-
E. Koller W.A. Gaarde B.P. Monia Elucidating cell signaling mechanisms using antisense technology Trends Pharmacol. Sci. 21 2000 142-148
-
(2000)
Trends Pharmacol. Sci.
, vol.21
, pp. 142-148
-
-
Koller, E.1
Gaarde, W.A.2
Monia, B.P.3
-
31
-
-
0041422172
-
Ribozymes: A modern tool in medicine
-
A.U. Khan S.K. Lal Ribozymes: A modern tool in medicine J. Biomed. Sci. 10 2003 457-467
-
(2003)
J. Biomed. Sci.
, vol.10
, pp. 457-467
-
-
Khan, A.U.1
Lal, S.K.2
-
32
-
-
0027197245
-
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
-
K.J. Kim et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841-844
-
(1993)
Nature
, vol.362
, pp. 841-844
-
-
Kim, K.J.1
-
33
-
-
0005620475
-
Aptamers as therapeutic and diagnostic agents
-
E.N. Brody L. Gold Aptamers as therapeutic and diagnostic agents J. Biotechnol. 74 2000 5-13
-
(2000)
J. Biotechnol.
, vol.74
, pp. 5-13
-
-
Brody, E.N.1
Gold, L.2
-
35
-
-
0035807251
-
Peptide aptamers targeting the hepatitis B virus core protein: A new class of molecules with antiviral activity
-
K. Butz et al. Peptide aptamers targeting the hepatitis B virus core protein: A new class of molecules with antiviral activity Oncogene 20 2001 6579-6586
-
(2001)
Oncogene
, vol.20
, pp. 6579-6586
-
-
Butz, K.1
-
36
-
-
0037062951
-
RNA interference
-
G.J. Hannon RNA interference Nature 418 2002 244-251
-
(2002)
Nature
, vol.418
, pp. 244-251
-
-
Hannon, G.J.1
-
38
-
-
0035905766
-
Role for a bidentate ribonuclease in the initiation step of RNA interference
-
E. Bernstein A.A. Caudy S.M. Hammond G.J. Hannon Role for a bidentate ribonuclease in the initiation step of RNA interference Nature 409 2001 363-366
-
(2001)
Nature
, vol.409
, pp. 363-366
-
-
Bernstein, E.1
Caudy, A.A.2
Hammond, S.M.3
Hannon, G.J.4
-
40
-
-
12144289681
-
A large-scale RNAi screen in human cells identifies new components of the p53 pathway
-
K. Berns et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway Nature 428 2004 431-437
-
(2004)
Nature
, vol.428
, pp. 431-437
-
-
Berns, K.1
-
41
-
-
0034581163
-
Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances
-
U. Baron H. Bujard Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances Methods Enzymol. 327 2000 401-421
-
(2000)
Methods Enzymol.
, vol.327
, pp. 401-421
-
-
Baron, U.1
Bujard, H.2
-
42
-
-
0036549015
-
Conditional mouse models of sporadic cancer
-
J. Jonkers A. Berns Conditional mouse models of sporadic cancer Nat. Rev. Cancer 2 2002 251-265
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 251-265
-
-
Jonkers, J.1
Berns, A.2
-
43
-
-
0035491607
-
Conditional control of gene expression in the mouse
-
M. Lewandoski Conditional control of gene expression in the mouse Nat. Rev. Genet. 2 2001 743-755
-
(2001)
Nat. Rev. Genet.
, vol.2
, pp. 743-755
-
-
Lewandoski, M.1
-
44
-
-
1542321226
-
Animal models of tumor immunity, immunotherapy and cancer vaccines
-
S. Ostrand-Rosenberg Animal models of tumor immunity, immunotherapy and cancer vaccines Curr. Opin. Immunol. 16 2004 143-150
-
(2004)
Curr. Opin. Immunol.
, vol.16
, pp. 143-150
-
-
Ostrand-Rosenberg, S.1
-
48
-
-
0034470397
-
Angiogenesis in transgenic models of multistep carcinogenesis
-
D.A. MG T. Afanasieva A. Aguzzi Angiogenesis in transgenic models of multistep carcinogenesis J. Neurooncol. 50 2000 89-98
-
(2000)
J. Neurooncol.
, vol.50
, pp. 89-98
-
-
MG, D.A.1
Afanasieva, T.2
Aguzzi, A.3
-
49
-
-
0030512608
-
Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
-
D. Hanahan G. Christofori P. Naik J. Arbeit Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models Eur. J. Cancer 32A 1996 2386-2393
-
(1996)
Eur. J. Cancer
, vol.32 A
, pp. 2386-2393
-
-
Hanahan, D.1
Christofori, G.2
Naik, P.3
Arbeit, J.4
-
50
-
-
1942518888
-
Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development
-
K. Hansen C. Khanna Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development Eur. J. Cancer 40 2004 858-880
-
(2004)
Eur. J. Cancer
, vol.40
, pp. 858-880
-
-
Hansen, K.1
Khanna, C.2
-
53
-
-
0036359767
-
Scaling down imaging: Molecular mapping of cancer in mice
-
R. Weissleder Scaling down imaging: Molecular mapping of cancer in mice Nat. Rev. Cancer 2 2002 11-18
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 11-18
-
-
Weissleder, R.1
-
54
-
-
84867502960
-
Tissue microarray (TMA) applications: Implications for molecular medicine
-
R. Simon G. Sauter Tissue microarray (TMA) applications: Implications for molecular medicine Expert Rev. Mol. Med. 2003 2003 1-12
-
(2003)
Expert Rev. Mol. Med.
, vol.2003
, pp. 1-12
-
-
Simon, R.1
Sauter, G.2
-
55
-
-
0034812398
-
Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies
-
L. Bubendorf A. Nocito H. Moch G. Sauter Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies J. Pathol. 195 2001 72-79
-
(2001)
J. Pathol.
, vol.195
, pp. 72-79
-
-
Bubendorf, L.1
Nocito, A.2
Moch, H.3
Sauter, G.4
-
56
-
-
0031822837
-
Tissue microarrays for high-throughput molecular profiling of tumor specimens
-
J. Kononen et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat. Med. 4 1998 844-847
-
(1998)
Nat. Med.
, vol.4
, pp. 844-847
-
-
Kononen, J.1
-
57
-
-
0036603905
-
Chemical space navigation in lead discovery
-
T.I. Oprea Chemical space navigation in lead discovery Curr. Opin. Chem. Biol. 6 2002 384-389
-
(2002)
Curr. Opin. Chem. Biol.
, vol.6
, pp. 384-389
-
-
Oprea, T.I.1
-
58
-
-
0037376928
-
Pharmaceutical profiling in drug discovery
-
E.H. Kerns L. Di Pharmaceutical profiling in drug discovery Drug Discovery Today 8 2003 316-323
-
(2003)
Drug Discovery Today
, vol.8
, pp. 316-323
-
-
Kerns, E.H.1
Di, L.2
-
59
-
-
0037468884
-
A comparison of physiochemical property profiles of development and marketed oral drugs
-
M.C. Wenlock R.P. Austin P. Barton A.M. Davis P.D. Leeson A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250-1256
-
(2003)
J. Med. Chem.
, vol.46
, pp. 1250-1256
-
-
Wenlock, M.C.1
Austin, R.P.2
Barton, P.3
Davis, A.M.4
Leeson, P.D.5
-
60
-
-
1242271305
-
Molecular recognition: The fragment approach in lead generation
-
D. Fattori Molecular recognition: The fragment approach in lead generation Drug Discovery Today 9 2004 229-238
-
(2004)
Drug Discovery Today
, vol.9
, pp. 229-238
-
-
Fattori, D.1
-
61
-
-
0038748179
-
Virtual screening of virtual libraries
-
D.V. Green Virtual screening of virtual libraries Prog. Med. Chem. 41 2003 61-97
-
(2003)
Prog. Med. Chem.
, vol.41
, pp. 61-97
-
-
Green, D.V.1
-
63
-
-
0041563779
-
Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors
-
Z. Fishelson N. Donin S. Zell S. Schultz M. Kirschfink Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors Mol. Immunol. 40 2003 109-123
-
(2003)
Mol. Immunol.
, vol.40
, pp. 109-123
-
-
Fishelson, Z.1
Donin, N.2
Zell, S.3
Schultz, S.4
Kirschfink, M.5
-
64
-
-
0036900866
-
Antibody manufacture in transgenic animals and comparisons with other systems
-
L.M. Houdebine Antibody manufacture in transgenic animals and comparisons with other systems Curr. Opin. Biotechnol. 13 2002 625-629
-
(2002)
Curr. Opin. Biotechnol.
, vol.13
, pp. 625-629
-
-
Houdebine, L.M.1
-
65
-
-
0036900286
-
Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics
-
S.A. Kellermann L.L. Green Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics Curr. Opin. Biotechnol. 13 2002 593-597
-
(2002)
Curr. Opin. Biotechnol.
, vol.13
, pp. 593-597
-
-
Kellermann, S.A.1
Green, L.L.2
-
67
-
-
0028222932
-
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
-
N. Lonberg et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications Nature 368 1994 856-859
-
(1994)
Nature
, vol.368
, pp. 856-859
-
-
Lonberg, N.1
-
69
-
-
0037323323
-
Developing novel oncolytic adenoviruses through bioselection
-
W. Yan et al. Developing novel oncolytic adenoviruses through bioselection J. Virol. 77 2003 2640-2650
-
(2003)
J. Virol.
, vol.77
, pp. 2640-2650
-
-
Yan, W.1
-
70
-
-
0035902471
-
Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells
-
S. Taneja J. MacGregor S. Markus S. Ha I. Mohr Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells Proc. Natl. Acad. Sci. USA 98 2001 8804-8808
-
(2001)
Proc. Natl. Acad. Sci. USA
, vol.98
, pp. 8804-8808
-
-
Taneja, S.1
MacGregor, J.2
Markus, S.3
Ha, S.4
Mohr, I.5
-
71
-
-
0037452445
-
Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection
-
F.P. Theil T.W. Guentert S. Haddad P. Poulin Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection Toxicol. Lett. 138 2003 29-49
-
(2003)
Toxicol. Lett.
, vol.138
, pp. 29-49
-
-
Theil, F.P.1
Guentert, T.W.2
Haddad, S.3
Poulin, P.4
-
72
-
-
1042302103
-
Early prediction of drug metabolism and toxicity: Systems biology approach and modeling
-
A. Bugrim T. Nikolskaya Y. Nikolsky Early prediction of drug metabolism and toxicity: Systems biology approach and modeling Drug Discovery Today 9 2004 127-135
-
(2004)
Drug Discovery Today
, vol.9
, pp. 127-135
-
-
Bugrim, A.1
Nikolskaya, T.2
Nikolsky, Y.3
-
73
-
-
0034002261
-
Role of the development scientist in compound lead selection and optimization
-
S. Venkatesh R.A. Lipper Role of the development scientist in compound lead selection and optimization J. Pharm. Sci. 89 2000 145-154
-
(2000)
J. Pharm. Sci.
, vol.89
, pp. 145-154
-
-
Venkatesh, S.1
Lipper, R.A.2
-
75
-
-
0036764768
-
Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells
-
B.G. Barnett B.W. Tillman D.T. Curiel J.T. Douglas Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells Mol. Ther. 6 2002 377-385
-
(2002)
Mol. Ther.
, vol.6
, pp. 377-385
-
-
Barnett, B.G.1
Tillman, B.W.2
Curiel, D.T.3
Douglas, J.T.4
-
76
-
-
0034086730
-
Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
-
K. Doronin K. Toth M. Kuppuswamy P. Ward A.E. Tollefson W.S. Wold Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein J. Virol. 74 2000 6147-6155
-
(2000)
J. Virol.
, vol.74
, pp. 6147-6155
-
-
Doronin, K.1
Toth, K.2
Kuppuswamy, M.3
Ward, P.4
Tollefson, A.E.5
Wold, W.S.6
-
77
-
-
0034917855
-
Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - Deletion of the viral E1b-19-kD gene increases the viral oncolytic effect
-
D. Harrison H. Sauthoff S. Heitner J. Jagirdar W.N. Rom J.G. Hay Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - Deletion of the viral E1b-19-kD gene increases the viral oncolytic effect Hum. Gene Ther. 12 2001 1323-1332
-
(2001)
Hum. Gene Ther.
, vol.12
, pp. 1323-1332
-
-
Harrison, D.1
Sauthoff, H.2
Heitner, S.3
Jagirdar, J.4
Rom, W.N.5
Hay, J.G.6
-
79
-
-
0036903141
-
Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes
-
T.W. Hermiston I. Kuhn Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes Cancer Gene Ther. 9 2002 1022-1035
-
(2002)
Cancer Gene Ther.
, vol.9
, pp. 1022-1035
-
-
Hermiston, T.W.1
Kuhn, I.2
-
80
-
-
0034628552
-
Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector
-
H. Sauthoff S. Heitner W.N. Rom J.G. Hay Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector Hum. Gene Ther. 11 2000 379-388
-
(2000)
Hum. Gene Ther.
, vol.11
, pp. 379-388
-
-
Sauthoff, H.1
Heitner, S.2
Rom, W.N.3
Hay, J.G.4
-
82
-
-
0037598911
-
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect
-
X. Fu L. Tao A. Jin R. Vile M.K. Brenner X. Zhang Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect Mol. Ther. 7 2003 748-754
-
(2003)
Mol. Ther.
, vol.7
, pp. 748-754
-
-
Fu, X.1
Tao, L.2
Jin, A.3
Vile, R.4
Brenner, M.K.5
Zhang, X.6
-
83
-
-
10744223476
-
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
-
D.F. Stojdl et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents Cancer Cell 4 2003 263-275
-
(2003)
Cancer Cell
, vol.4
, pp. 263-275
-
-
Stojdl, D.F.1
-
84
-
-
0344188096
-
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
-
J.R. Bischoff et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373-376
-
(1996)
Science
, vol.274
, pp. 373-376
-
-
Bischoff, J.R.1
-
85
-
-
0030790684
-
Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
-
R. Rodriguez E.R. Schuur H.Y. Lim G.A. Henderson J.W. Simons D.R. Henderson Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res. 57 1997 2559-2563
-
(1997)
Cancer Res.
, vol.57
, pp. 2559-2563
-
-
Rodriguez, R.1
Schuur, E.R.2
Lim, H.Y.3
Henderson, G.A.4
Simons, J.W.5
Henderson, D.R.6
-
86
-
-
0242290921
-
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models
-
Y. Wang et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models Nat. Biotechnol. 21 2003 1328-1335
-
(2003)
Nat. Biotechnol.
, vol.21
, pp. 1328-1335
-
-
Wang, Y.1
-
87
-
-
0034022622
-
Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
-
T. Hermiston Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer J. Clin. Invest. 105 2000 1169-1172
-
(2000)
J. Clin. Invest.
, vol.105
, pp. 1169-1172
-
-
Hermiston, T.1
-
88
-
-
0033831080
-
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
-
F.R. Khuri et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat. Med. 6 2000 879-885
-
(2000)
Nat. Med.
, vol.6
, pp. 879-885
-
-
Khuri, F.R.1
-
89
-
-
0032503659
-
A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
-
S.O. Freytag K.R. Rogulski D.L. Paielli J.D. Gilbert J.H. Kim A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy Hum. Gene Ther. 9 1998 1323-1333
-
(1998)
Hum. Gene Ther.
, vol.9
, pp. 1323-1333
-
-
Freytag, S.O.1
Rogulski, K.R.2
Paielli, D.L.3
Gilbert, J.D.4
Kim, J.H.5
-
90
-
-
0035030198
-
Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors
-
E. Galanis R. Vile S.J. Russell Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors Crit. Rev. Oncol. Hematol. 38 2001 177-192
-
(2001)
Crit. Rev. Oncol. Hematol.
, vol.38
, pp. 177-192
-
-
Galanis, E.1
Vile, R.2
Russell, S.J.3
-
91
-
-
0036901290
-
Adenoviral vectors: Systemic delivery and tumor targeting
-
N.K. Green L.W. Seymour Adenoviral vectors: Systemic delivery and tumor targeting Cancer Gene Ther. 9 2002 1036-1042
-
(2002)
Cancer Gene Ther.
, vol.9
, pp. 1036-1042
-
-
Green, N.K.1
Seymour, L.W.2
-
92
-
-
0036376654
-
Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery?
-
K. Harrington et al. Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery? Hum. Gene Ther. 13 2002 1263-1280
-
(2002)
Hum. Gene Ther.
, vol.13
, pp. 1263-1280
-
-
Harrington, K.1
-
93
-
-
0030917202
-
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
-
C. Heise A. Sampson-Johannes A. Williams F. McCormick D.D. Von Hoff D.H. Kirn ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat. Med. 3 1997 639-645
-
(1997)
Nat. Med.
, vol.3
, pp. 639-645
-
-
Heise, C.1
Sampson-Johannes, A.2
Williams, A.3
McCormick, F.4
Von Hoff, D.D.5
Kirn, D.H.6
-
94
-
-
0033012742
-
Preclinical development strategies for novel gene therapeutic products
-
A.M. Pilaro M.A. Serabian Preclinical development strategies for novel gene therapeutic products Toxicol. Pathol. 27 1999 4-7
-
(1999)
Toxicol. Pathol.
, vol.27
, pp. 4-7
-
-
Pilaro, A.M.1
Serabian, M.A.2
-
95
-
-
0035992427
-
Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder
-
K. Inoue M. Chikazawa S. Fukata C. Yoshikawa T. Shuin Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder Clin. Cancer Res. 8 2002 2389-2398
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 2389-2398
-
-
Inoue, K.1
Chikazawa, M.2
Fukata, S.3
Yoshikawa, C.4
Shuin, T.5
-
96
-
-
9144266295
-
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
-
S.R. Hingorani et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437-450
-
(2003)
Cancer Cell
, vol.4
, pp. 437-450
-
-
Hingorani, S.R.1
-
97
-
-
0033665576
-
Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status
-
C. Heise I. Ganly Y.T. Kim A. Sampson-Johannes R. Brown D. Kirn Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status Gene Ther. 7 2000 1925-1929
-
(2000)
Gene Ther.
, vol.7
, pp. 1925-1929
-
-
Heise, C.1
Ganly, I.2
Kim, Y.T.3
Sampson-Johannes, A.4
Brown, R.5
Kirn, D.6
-
98
-
-
0029830054
-
Natural resistance against tumors grafted into the brain in association with histocompatibility-class-I-antigen expression
-
T. Yamasaki et al. Natural resistance against tumors grafted into the brain in association with histocompatibility-class-I-antigen expression Int. J. Cancer 67 1996 365-371
-
(1996)
Int. J. Cancer
, vol.67
, pp. 365-371
-
-
Yamasaki, T.1
-
99
-
-
11144355464
-
Classification of proliferative pulmonary lesions of the mouse: Recommendations of the Mouse Models of Human Cancers Consortium
-
A.Y. Nikitin et al. Classification of proliferative pulmonary lesions of the mouse: Recommendations of the Mouse Models of Human Cancers Consortium Cancer Res. 64 2004 2307-2316
-
(2004)
Cancer Res.
, vol.64
, pp. 2307-2316
-
-
Nikitin, A.Y.1
-
100
-
-
0842332343
-
A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens
-
C.J. Buskens et al. A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens Ann. Surg. 238 2003 815-824
-
(2003)
Ann. Surg.
, vol.238
, pp. 815-824
-
-
Buskens, C.J.1
-
101
-
-
0242287933
-
Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors
-
V.W. van Beusechem et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors Gene Ther. 10 2003 1982-1991
-
(2003)
Gene Ther.
, vol.10
, pp. 1982-1991
-
-
van Beusechem, V.W.1
-
102
-
-
0141632785
-
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy
-
G. Hallden et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy Mol. Ther. 8 2003 412-424
-
(2003)
Mol. Ther.
, vol.8
, pp. 412-424
-
-
Hallden, G.1
-
103
-
-
0036841845
-
TNFerade biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene
-
H. Rasmussen et al. TNFerade biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene Cancer Gene Ther. 9 2002 951-957
-
(2002)
Cancer Gene Ther.
, vol.9
, pp. 951-957
-
-
Rasmussen, H.1
-
104
-
-
0034150206
-
Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse
-
D.L. Paielli et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse Mol. Ther. 1 2000 263-274
-
(2000)
Mol. Ther.
, vol.1
, pp. 263-274
-
-
Paielli, D.L.1
-
105
-
-
0036905005
-
Biosafety and product release testing issues relevant to replication-competent oncolytic viruses
-
M. Wisher Biosafety and product release testing issues relevant to replication-competent oncolytic viruses Cancer Gene Ther. 9 2002 1056-1061
-
(2002)
Cancer Gene Ther.
, vol.9
, pp. 1056-1061
-
-
Wisher, M.1
-
106
-
-
0036828125
-
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints
-
T. Reid et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints Cancer Res. 62 2002 6070-6079
-
(2002)
Cancer Res.
, vol.62
, pp. 6070-6079
-
-
Reid, T.1
-
107
-
-
0035177690
-
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial
-
T. Reid et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial Gene Ther. 8 2001 1618-1626
-
(2001)
Gene Ther.
, vol.8
, pp. 1618-1626
-
-
Reid, T.1
-
108
-
-
0037314655
-
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies
-
D. Makower et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies Clin. Cancer Res. 9 2003 693-702
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 693-702
-
-
Makower, D.1
-
109
-
-
12944315014
-
Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: Results of a phase I trial
-
J.M. Markert et al. Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: Results of a phase I trial Gene Ther. 7 2000 867-874
-
(2000)
Gene Ther.
, vol.7
, pp. 867-874
-
-
Markert, J.M.1
-
110
-
-
0033193127
-
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
-
M.J. Mastrangelo et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma Cancer Gene Ther. 6 1999 409-422
-
(1999)
Cancer Gene Ther.
, vol.6
, pp. 409-422
-
-
Mastrangelo, M.J.1
-
111
-
-
0035887153
-
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
-
T.L. DeWeese et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy Cancer Res. 61 2001 7464-7472
-
(2001)
Cancer Res.
, vol.61
, pp. 7464-7472
-
-
DeWeese, T.L.1
-
112
-
-
0036733759
-
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer
-
S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res. 62 2002 4968-4976
-
(2002)
Cancer Res.
, vol.62
, pp. 4968-4976
-
-
Freytag, S.O.1
-
113
-
-
0033693231
-
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
-
J. Nemunaitis et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial Cancer Res. 60 2000 6359-6366
-
(2000)
Cancer Res.
, vol.60
, pp. 6359-6366
-
-
Nemunaitis, J.1
-
114
-
-
0034111270
-
Development of target-based antineoplastic agents
-
W.M. Stadler M.J. Ratain Development of target-based antineoplastic agents Invest. New Drugs 18 2000 7-16
-
(2000)
Invest. New Drugs
, vol.18
, pp. 7-16
-
-
Stadler, W.M.1
Ratain, M.J.2
-
115
-
-
10744227813
-
Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer
-
S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer Cancer Res. 63 2003 7497-7506
-
(2003)
Cancer Res.
, vol.63
, pp. 7497-7506
-
-
Freytag, S.O.1
-
116
-
-
1342290237
-
AACR-NCL-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
T. Hermiston D. Kirn AACR-NCL-EORTC International Conference on Molecular Targets and Cancer Therapeutics Mol. Ther. 9 2004 144-146
-
(2004)
Mol. Ther.
, vol.9
, pp. 144-146
-
-
Hermiston, T.1
Kirn, D.2
-
117
-
-
0141973782
-
The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision
-
T.G. Roberts Jr. T.J. Lynch Jr. B.A. Chabner The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision J. Clin. Oncol. 21 2003 3683-3695
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 3683-3695
-
-
Roberts Jr., T.G.1
Lynch Jr., T.J.2
Chabner, B.A.3
-
118
-
-
0037811751
-
Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial?
-
D.H. Johnson C.L. Arteaga Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial? J. Clin. Oncol. 21 2003 2227-2229
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 2227-2229
-
-
Johnson, D.H.1
Arteaga, C.L.2
-
119
-
-
0037112181
-
Randomized discontinuation design: Application to cytostatic antineoplastic agents
-
G.L. Rosner W. Stadler M.J. Ratain Randomized discontinuation design: application to cytostatic antineoplastic agents J. Clin. Oncol. 20 2002 4478-4484
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 4478-4484
-
-
Rosner, G.L.1
Stadler, W.2
Ratain, M.J.3
-
120
-
-
10744220743
-
Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
-
J.R. Johnson et al. Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase Clin. Cancer Res. 9 2003 1972-1979
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 1972-1979
-
-
Johnson, J.R.1
-
121
-
-
0345447210
-
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
-
R.C. Kane P.F. Bross A.T. Farrell R. Pazdur Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy Oncologist 8 2003 508-513
-
(2003)
Oncologist
, vol.8
, pp. 508-513
-
-
Kane, R.C.1
Bross, P.F.2
Farrell, A.T.3
Pazdur, R.4
-
122
-
-
12144287534
-
United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets
-
M.H. Cohen et al. United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets Clin. Cancer Res. 10 2004 1212-1218
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 1212-1218
-
-
Cohen, M.H.1
-
123
-
-
0037010079
-
Epidermal growth factor receptor-targeted therapy in colorectal cancer
-
P.J. O'Dwyer A.B. Benson III Epidermal growth factor receptor-targeted therapy in colorectal cancer Semin. Oncol. 29 2002 10-17
-
(2002)
Semin. Oncol.
, vol.29
, pp. 10-17
-
-
O'Dwyer, P.J.1
Benson III, A.B.2
-
124
-
-
1442332187
-
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors
-
N. Senzer et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors J. Clin. Oncol. 22 2004 592-601
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 592-601
-
-
Senzer, N.1
|